Gelomics is an Australian deep-tech biotechnology company revolutionising drug development by replacing animal testing with human-relevant 3D cell culture technologies. Founded in 2018 and headquartered in Brisbane, Gelomics designs and manufactures cutting-edge platforms that enable the growth of functional human tissues in vitro. Our integrated LunaXTM System—combining proprietary hydrogels, advanced photopolymerisation devices, and AI-driven software—empowers pharmaceutical and research institutions worldwide to develop safer, more effective therapies, faster.

Gelomics serves over 23 international markets across North America, Europe, Asia-Pacific, and the Middle East, with clients including leading academic institutions, CROs, and multinational pharmaceutical companies. Our mission is to accelerate life science innovation through ethical, scalable, and predictive non-animal models.

Why work with us

• Human-Relevant Alternatives: Our 3D tissue culture platforms offer unparalleled reproducibility, biological relevance, and scalability, significantly improving preclinical predictability over traditional animal models and 2D cultures.
• Integrated AI & Hardware: We are the only company globally offering an integrated system of AI-augmented software, precision-engineered devices, and chemically defined ECMs for complete experimental control.
• Global Track Record: With >80% demo-to-sale conversion and a customer base spanning 23+ countries, we have proven our capacity to deliver impact at scale.
• Trusted by Industry Leaders: We partner with pharmaceutical giants, hospitals, and research institutes to drive innovation in oncology, immunology, and personalised medicine.
• Sustainably Manufactured in Australia: All products are developed and manufactured in our ISO-certified Brisbane facility, supporting Australia's sovereign biotech capabilities.